BICARA THERAPEUTICS INC
BCAXNASDAQ🏆 #2696 by market capEarnings Nov 17US Equity
$9.72▼ $7.78 (−44.46%)
Pre-market · at closeTrack BCAX
Get earnings, price moves & breaking news on Telegram
24h▼ 44.5%
7d▼ 44.8%
14d▼ 44.9%
30d▼ 47.5%
ytd▼ 42.2%
1y▼ 38.8%
🏦Market Cap
$643M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Fair
Trading Snapshot
- Day Range
- $8.90 – $17.33
- 52-Week Range
- $8.90 – $30.99
- Volume (shares)
- 751,319
- Avg Volume (shares)
- —
- Shares Outstanding
- 66.2M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -3.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.73
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.3%
BICARA THERAPEUTICS INC
BCAXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$156M▲ +88.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$107M▲ +43.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
55.1M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$95M▼ −$394M YoY
StockOtter · stockotter.spaceAbout BICARA THERAPEUTICS INC
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
52/100
Analyst Ratings
ⓘConsensus
Buy
20 analysts
Strong Buy7
Buy11
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.